1
Lisa A. de Jong, Judith J. Gout-Zwart, Jelena Stevanovic, Harrie Rila, Mike Koops, Menno V. Huisman, Maarten J. Postma
Veröffentlicht in: TH Open, Vol 02, Iss 03, Pp e315-e324 (2018);
2018
Veröffentlicht in: TH Open, Vol 02, Iss 03, Pp e315-e324 (2018);
2018
2
De Jong, Lisa A., Gout-Zwart, Judith J., Stevanovic, Jelena, Rila, Harrie, Koops, Mike, Huisman, Menno V., Postma, Maarten J.
Veröffentlicht in: De Jong , L A , Gout-Zwart , J J , Stevanovic , J , Rila , H , Koops , M , Huisman , M V & Postma , M J 2018 , ' Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands : Clinical and Economic Effects ' , BMJ Open , vol. 2 , no. 3 , pp. e315-e324 . https://doi.org/10.1055/s-0038-1672185;
2018
Veröffentlicht in: De Jong , L A , Gout-Zwart , J J , Stevanovic , J , Rila , H , Koops , M , Huisman , M V & Postma , M J 2018 , ' Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands : Clinical and Economic Effects ' , BMJ Open , vol. 2 , no. 3 , pp. e315-e324 . https://doi.org/10.1055/s-0038-1672185;
2018
3
de Jong, Lisa A, Dvortsin, Evgeni, Janssen, Kristel J., Postma, Maarten J.
Veröffentlicht in: de Jong , L A , Dvortsin , E , Janssen , K J & Postma , M J 2017 , ' Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands ' , Clinical Therapeutics , vol. 39 , no. 2 , pp. 288-302 . https://doi.org/10.1016/j.clinthera.2016.12.012;
2017
Veröffentlicht in: de Jong , L A , Dvortsin , E , Janssen , K J & Postma , M J 2017 , ' Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands ' , Clinical Therapeutics , vol. 39 , no. 2 , pp. 288-302 . https://doi.org/10.1016/j.clinthera.2016.12.012;
2017